Format

Send to

Choose Destination
Bone Marrow Transplant. 2015 Sep;50(9):1241-9. doi: 10.1038/bmt.2015.137. Epub 2015 Jun 15.

Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia.

Author information

1
Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
2
Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan.
3
Division of Hematology, Keio University School of Medicine, Tokyo, Japan.
4
Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
5
Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
6
Department of Hematology, Fujita Health University, Toyoake, Japan.
7
Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
8
Department of Hematology and Oncology, JA Aichi Konan Kosei Hospital, Konan, Japan.
9
Department of Hematology, Chiba University Hospital, Chiba, Japan.
10
Division of Hematology, Department of Medicine, Showa University, Tokyo, Japan.
11
Department of Hematology and Oncology, Kyoto University, Kyoto, Japan.
12
Department of Hematology, Osaka City University, Osaka, Japan.
13
Division of Hematology, Ehime Prefectural Central Hospital, Matsuyama, Japan.
14
Department of Pediatrics, Tokai University School of Medicine, Isehara, Japan.
15
NPO Blood Disorder Information and Support Service, Tsubasa, Tokyo, Japan.

Abstract

When discussing treatment options for patients with acute leukemia, it is important to acknowledge the impact of allogeneic hematopoietic cell transplantation (allo-HCT) or chemotherapy on quality of life (QOL). We performed a cross-sectional questionnaire study that administered SF-36, FACT-Leukemia and EuroQOL5D to 524 acute leukemia survivors, to compare patient-reported QOL between chemotherapy and allo-HCT, and to elucidate predictors of QOL. Patients who received chemotherapy alone had a better physical QOL than those who received allo-HCT. On the other hand, the allo-HCT group reported a better mental QOL. In the comparison of QOL in the allo-HCT patients according to the presence of GVHD at survey, patients who had GVHD symptoms experienced statistically and clinically significantly worse QOL than those who did not. In the allo-HCT patients without GVHD, the physical QOL was comparable to that in the chemotherapy patients, and they experienced significantly better mental and general QOL than the chemotherapy patients. GVHD and immunosuppressive drugs at survey were strongly associated with worse QOL after allo-HCT. In the chemotherapy group, a shorter time between treatment completion and survey was significantly associated with worse QOL. Further evaluation of QOL by a longitudinal assessment with quantitative and qualitative analyses are warranted.

PMID:
26076127
DOI:
10.1038/bmt.2015.137
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center